Pfizer Inc.
PFENYSEHealthcare● Active
$25.62
$-0.42(-1.61%)
Market Cap$146.0B
P/E Ratio—
52W High$28.75
52W Low$23.11
Pfizer Inc. (PFE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PFE · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.75
Est. $0.72 · +3.9%
Revenue
$14.45B
Est. $13.84B · +4.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
PFE reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.68 | — | — | — | $14.44B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.72 | $0.75 | +3.9% | $14.45B | $13.84B | +4.4% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $0.57 | $0.66 | +16.4% | $17.56B | $16.85B | +4.2% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.63 | $0.87 | +37.4% | $16.65B | $16.50B | +0.9% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.58 | $0.78 | +34.5% | $14.65B | $13.56B | +8.1% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $0.67 | $0.92 | +38.1% | $13.71B | $13.92B | -1.5% |
| ▲ Q1 FY2025 | Feb 4, 2025 | $0.47 | $0.63 | +33.6% | $17.76B | $17.35B | +2.4% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $0.61 | $1.06 | +72.6% | $17.70B | $14.92B | +18.6% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.68
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.75
EPS Est.
$0.72
EPS Surpr.
+3.9%
Revenue
$14.45B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$0.66
EPS Est.
$0.57
EPS Surpr.
+16.4%
Revenue
$17.56B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.87
EPS Est.
$0.63
EPS Surpr.
+37.4%
Revenue
$16.65B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.78
EPS Est.
$0.58
EPS Surpr.
+34.5%
Revenue
$14.65B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$0.92
EPS Est.
$0.67
EPS Surpr.
+38.1%
Revenue
$13.71B
Q1 FY2025
Feb 4, 2025Beat
EPS Actual
$0.63
EPS Est.
$0.47
EPS Surpr.
+33.6%
Revenue
$17.76B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$1.06
EPS Est.
$0.61
EPS Surpr.
+72.6%
Revenue
$17.70B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.55 | $0.58 | $0.60 | 4 |
| Q3 FY2027 | $0.76 | $0.81 | $0.84 | 7 |
| Q2 FY2027 | $0.59 | $0.63 | $0.65 | 4 |
| Q1 FY2027 | $0.59 | $0.63 | $0.65 | 4 |
| Q4 FY2026 | $0.65 | $0.69 | $0.72 | 9 |
| Q3 FY2026 | $0.81 | $0.85 | $0.89 | 11 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $15.4B | $16.1B | $16.6B | 7 |
| Q3 FY2027 | $15.0B | $15.7B | $16.2B | 4 |
| Q2 FY2027 | $13.4B | $14.0B | $14.4B | 4 |
| Q1 FY2027 | $12.7B | $13.3B | $13.6B | 7 |
| Q4 FY2026 | $16.1B | $16.8B | $17.3B | 6 |
| Q3 FY2026 | $16.0B | $16.2B | $16.7B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +3.9% | $26.30 | $26.45 | +0.57% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +16.4% | $26.66 | $25.77 | -3.34% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +37.4% | $24.66 | $24.30 | -1.46% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +34.5% | $23.53 | $24.75 | +5.18% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +38.1% | $23.05 | $23.79 | +3.21% |
| ▲ Q1 FY2025 | Feb 4, 2025 | +33.6% | $26.20 | $25.87 | -1.26% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +72.6% | $28.86 | $28.46 | -1.39% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +31.0% | $30.72 | $31.39 | +2.18% |
Q2 FY2026+0.57%
Report Date
May 5, 2026
EPS Beat/Miss
+3.9%
Price Before
$26.30
Price After
$26.45
Q1 FY2026-3.34%
Report Date
Feb 3, 2026
EPS Beat/Miss
+16.4%
Price Before
$26.66
Price After
$25.77
Q4 FY2025-1.46%
Report Date
Nov 4, 2025
EPS Beat/Miss
+37.4%
Price Before
$24.66
Price After
$24.30
Q3 FY2025+5.18%
Report Date
Aug 5, 2025
EPS Beat/Miss
+34.5%
Price Before
$23.53
Price After
$24.75
Q2 FY2025+3.21%
Report Date
Apr 29, 2025
EPS Beat/Miss
+38.1%
Price Before
$23.05
Price After
$23.79
Q1 FY2025-1.26%
Report Date
Feb 4, 2025
EPS Beat/Miss
+33.6%
Price Before
$26.20
Price After
$25.87
Q4 FY2024-1.39%
Report Date
Oct 29, 2024
EPS Beat/Miss
+72.6%
Price Before
$28.86
Price After
$28.46
Q3 FY2024+2.18%
Report Date
Jul 30, 2024
EPS Beat/Miss
+31.0%
Price Before
$30.72
Price After
$31.39
Avg Beat Reaction+0.46%
Beat Rate8 / 8 quarters
Largest Move+5.18% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PFE ends December
Pfizer Inc. (PFE) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.75 — beating the analyst consensus of $0.72 by +3.9%. PFE has beaten EPS estimates for 11 consecutive quarters.
Each quarter, investors track PFE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PFE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PFE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PFE earnings · 5 questionsPfizer Inc.'s next earnings report is expected around TBD. PFE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PFE historically reports after market close (AMC).
PFE earnings datewhen is PFE earningsPFE next earnings datewhen does PFE report earningsPFE earnings calendar
▸ Source: FMP · Pfizer Inc. SEC filings · US GAAP · Pfizer Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026